PT-141 (bremelanotide)
FDA label for a specific indication
FDA-approved drug — specific formulations and indications
FDA approved as a specific ready-to-use autoinjector for the labeled indication. Source: Bremelanotide — FDA prescribing information, sections 1–5 and 12.1
Also listed as: PT-141, bremelanotide
What it is
A melanocortin receptor agonist. Source: Bremelanotide — FDA prescribing information, sections 1–5 and 12.1
What it has been studied for
Acquired, generalized hypoactive sexual desire disorder in premenopausal women under the labeled criteria. Source: Bremelanotide — FDA prescribing information, sections 1–5 and 12.1
Mechanism
Activates melanocortin receptors; the mechanism for the labeled benefit is not fully known. Source: Bremelanotide — FDA prescribing information, sections 1–5 and 12.1
Documented dosing
1.75 mg · Subcutaneous — labeled ready-to-use autoinjector
As needed, at least 45 minutes before anticipated activity; no more than once per 24 hours or 8 doses per month.
The label calls for a response review after 8 weeks.
Bremelanotide — FDA prescribing information, sections 1–5 and 12.1Pairings & cautions
No evidence-based peptide pairing is specified in this entry.
Contraindicated with uncontrolled hypertension or known cardiovascular disease; nausea and temporary blood pressure elevation can occur. Source: Bremelanotide — FDA prescribing information, sections 1–5 and 12.1
The labeled 1.75 mg in 0.3 mL is a prefilled autoinjector, not a reconstitution vial. Source: Bremelanotide — FDA prescribing information, sections 1–5 and 12.1
These are selected considerations, not a complete safety review. Discuss the full source and your medications with your prescriber.